- With a win in lung cancer, biotech’s wealthiest outsider surfs to new heights STAT
- Merck stock falls on Summit cancer drug’s trial results Yahoo Finance
- Summit Declares NSCLC Victory Over Keytruda, Analysts Advise Caution With China-Only Data BioSpace
- Akeso, Summit’s PD-1 bispecific crushes…
[ad_2]
Source link